+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating GLB-001, an oral drug, in a first-in-human Phase 1 clinical trial for adults with relapsed or refractory acute myeloid leukemia RR AML or relapsed or refractory higher-risk myelodysplastic syndromes RR HR-MDS. The study aims to assess the safety, tolerability, how the drug moves and acts in the body, and initial effectiveness. The trial includes a dose escalation phase to find the highest safe dose and a dose expansion phase to confirm tolerability and explore clinical activity. The trial uses a standard dose-escalation design in Phase 1a to evaluate several dose levels of GLB-001, adjusting dose amounts or frequency based on safety and pharmacokinetic data. After determining the maximum tolerated or administered dose, Phase 1b will enroll participants at one or two selected dose levels to confirm tolerability and assess whether the drug shows enough activity to continue development. GLB-001 is given orally based on the assigned treatment schedule. Participants will be closely monitored for dose-limiting toxicities during the first 28 days, as well as adverse events over up to two years. Researchers will measure drug levels in the body, response rates such as remission, progression-free survival, and overall survival. Safety reviews will guide dose selection for future studies. The total study duration includes long-term follow-up to track outcomes and safety for up to two years after treatment begins.

Age: 18Years +All GendersPhase 1
8 locations
A

Actively Recruiting

Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.

Age: 18Years +All GendersPhase 3
366 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of ponsegromab combined with systemic chemotherapy compared to chemotherapy plus placebo for adults with metastatic pancreatic ductal adenocarcinoma mPDAC who have cachexia, a condition causing significant weight loss and fatigue. This Phase 2b3, randomized, double-blind study involves adult participants who have completed initial chemotherapy cycles and aims to improve treatment outcomes for this challenging condition. Participants will receive either one of two doses of ponsegromab or a placebo alongside first-line chemotherapy regimens consisting of nab-paclitaxel plus gemcitabine or FOLFIRINOX. The study intervention is given as a subcutaneous injection every four weeks. After an initial Phase 2b period where doses are evaluated, the study continues into Phase 3 with the selected ponsegromab dose or placebo. Participants may also join an optional open-label extension to receive ponsegromab for up to 12 months after the double-blind phase ends. During the study, participants will have tumor assessments approximately every 6 to 8 weeks by independent radiologists. The research team will monitor body weight changes, physical activity, quality of life measures, safety events, and survival outcomes over the course of the trial, which may last up to several years. Caregiver quality of life is also evaluated in an optional sub-study. Participants health and treatment effects will be closely followed until the studys completion in 2029.

Age: 18Years +All GendersPhase 2Phase 3
230 locations
C

Actively Recruiting

Researchers are studying a medicine called elranatamab to treat multiple myeloma MM, a type of cancer. This study compares elranatamab with other common combination therapies for people with MM that has returned or not responded to previous treatments, including anti-CD38 antibody and lenalidomide. The study is sponsored by Pfizer and is a phase 3, open-label trial evaluating treatment options for adults with relapsed or refractory MM. Participants will be randomly assigned to receive either elranatamab alone or one of several combination therapies chosen by the study doctor. Elranatamab is given as a shot under the skin at the clinic about once a week, which may reduce in frequency later. Combination therapies include two to three different medicines taken orally or by injection at the clinic, with dosing schedules depending on the selected regimen. Treatment continues until the disease no longer responds. During the study, participants will have regular clinic visits to monitor their response and safety while receiving treatment. After treatment ends, follow-up will be done by phone or clinic visits. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, duration of response, and quality of life over approximately five years. Safety and laboratory tests will also be monitored throughout and shortly after treatment completion.

Age: 18Years +All GendersPhase 3
270 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.

Age: 18Years +All GendersPhase 2Phase 3
770 locations
P

Actively Recruiting

Researchers are evaluating AMG 509 in people with metastatic castration-resistant prostate cancer mCRPC to assess its safety, tolerability, how the body processes the drug, and preliminary effectiveness. The study includes participants who have received various prior treatments such as novel hormonal therapies and taxane chemotherapy. This is a Phase 1 trial with multiple parts, including expansion cohorts, some of which are open for enrollment as of July 2025. The trial tests AMG 509 given either as an intravenous IV infusion or subcutaneous SC injection, alone or combined with oral drugs abiraterone acetate or enzalutamide. Different parts of the study focus on different patient groups and dosing strategies, including dose exploration to find the maximum tolerated dose and recommended phase 2 dose. Some parts also examine AMG 509 given in outpatient infusion centers, with specific cohorts enrolled in China to confirm safety and dosing. Participants undergo screening to confirm eligibility, followed by treatment phases where AMG 509 and combinations are administered according to assigned study parts. Throughout the study, safety is monitored by tracking adverse events, vital signs, ECGs, and lab tests over several years. Effectiveness is assessed using tumor response criteria, prostate-specific antigen levels, and imaging studies. The trial includes long-term follow-up to evaluate treatment outcomes and pharmacokinetics over up to three years.

Age: 18Years +MALEPhase 1
57 locations
C

Actively Recruiting

Researchers are evaluating the cancer vaccine OSE2101 compared to the chemotherapy drug docetaxel in patients with metastatic non-small cell lung cancer NSCLC who have developed resistance to immune checkpoint inhibitors. This phase 3, randomized, open-label study focuses on HLA-A2 positive patients with either squamous or non-squamous NSCLC who are not candidates for surgery or radiation and lack certain genetic alterations that make them eligible for targeted therapies. Participants will be randomly assigned in a 21 ratio to receive either OSE2101 or docetaxel. OSE2101 is given as a subcutaneous injection every three weeks for six cycles, then every eight weeks for the first year, and finally every twelve weeks until the end of the second year. Docetaxel is administered as an intravenous infusion every three weeks. The study also uses companion diagnostic devices to confirm HLA-A2 status. Throughout the study, participants will have regular visits for treatment and monitoring. Researchers will measure overall survival from randomization until death, with an average follow-up of three years. The trial aims to assess the safety and effectiveness of OSE2101 compared to docetaxel in this patient group, with ongoing monitoring until study completion in late 2028.

Age: 18Years +All GendersPhase 3
207 locations